Internal Med Medical News about Multiple Sclerosis Interferon-beta1b

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: Design and lessons from a 16-year observational study
Clinical Therapeutics, 10/16/09

Ebers GC et al. – Although most patients (88.2%) were identified at long–term follow–up (LTF), ascertainment was incomplete. This was attributable to patients' refusal to participate, loss to follow–up, or death. Delays in the registration of death data and recent privacy legislation provided further barriers. Mortality was lower for patients originally randomized to receive IFN–beta1b rather than placebo. The authors recommend that all short–term trials on chronic diseases include provisions for LTF.

<< Previous
Managing myelodysplastic symptoms in elderly patients

Next >>
Interference Studies with Two Hospital-Grade and Two Home-Grade...

Early Psychiatric Manifestation in a Patient with Primary Progressive Multiple Sclerosis
Archives of Iranian Medicine, 11/12/09 Relevance Score: 69%

Cochlear implantation in a profoundly deaf patient who also suffers from multiple sclerosis - a case study
Cochlear Implants International, 10/27/09 Relevance Score: 69%

A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
Multiple Sclerosis, 10/01/09 Relevance Score: 69%

Regulatory and pro-inflammatory phenotypes of myelin basic protein-autoreactive T cells in multiple sclerosis
International Immunology, 10/14/09 Relevance Score: 68%

Early Drug Treatment May Cut Multiple Sclerosis Risk
MedLinePlus, 10/08/09 Relevance Score: 68%